Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

P. Cannon, Christopher; Cariou, Bertrand; Blom, Dirk; M. McKenney, James; Lorenzato, Christelle; Pordy, Robert; Chaudhari, Umesh; M. Colhoun, Helen

doi:10.1093/eurheartj/ehv028

Public

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Published in European Heart Journal • Feb 16, 2015

Authors:

Christopher P. Cannon

Bertrand Cariou

Dirk Blom

Abstract

AIMS: To compare the efficacy [low-density lipoprotein cholesterol (LDL-C) lowering] and safety of alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin 9, compared with ezetimibe, as add-on therapy to maximally tolerated statin therapy in high cardiovascular risk p...

Subject

Alirocumab

Medicine

Ezetimibe

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!